Naldemedine
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326729

CAS#: 916072-89-4

Description: Naldemedine, also known as S 297995, is a peripherally-selective μ-opioid receptor antagonist under development by Shionogi for the treatment of opioid-induced adverse effects including constipation, nausea, and vomiting. Clinical studies have thus far found it to possess statistically significant effectiveness for these indications and to be generally well-tolerated with predominantly mild to moderate gastrointestinal side effects. No effects indicative of central opioid withdrawal or impact on the analgesic or mydriatic effects of co-administered opioids have been observed.


Price and Availability

Size
Price

Size
Price

Size
Price

Naldemedine is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 326729
Name: Naldemedine
CAS#: 916072-89-4
Chemical Formula: C32H34N4O6
Exact Mass: 570.2478
Molecular Weight: 570.646
Elemental Analysis: C, 67.35; H, 6.01; N, 9.82; O, 16.82


Synonym: S 297995; S-297995; S297995; S 297,995; S-297,995; S297,995;Naldemedine

IUPAC/Chemical Name: 17-(cyclopropylmethyl)-6,7-didehydro-4,5alpha-epoxy-3,6,14-trihydroxy-N-(2-(3-phenyl- 1,2,4-oxadiazol-5-yl)propan-2-yl)morphinan-7-carboxamide

InChi Key: AXQACEQYCPKDMV-PFMBVUTNSA-N

InChi Code: InChI=1S/C32H34N4O6/c1-30(2,29-33-27(35-42-29)18-6-4-3-5-7-18)34-28(39)20-15-32(40)22-14-19-10-11-21(37)25-23(19)31(32,26(41-25)24(20)38)12-13-36(22)16-17-8-9-17/h3-7,10-11,17,22,26,37-38,40H,8-9,12-16H2,1-2H3,(H,34,39)/t22-,26-,31+,32-/m1/s1

SMILES Code: O=C(C1=C(O)[C@@H]2[C@]34C5=C(O2)C(O)=CC=C5C[C@@H](N(CC6CC6)CC4)[C@]3(O)C1)NC(C)(C7=NC(C8=CC=CC=C8)=NO7)C


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Webster L, Nagata T, Yamada T, Arjona Ferreira J. (479) A phase 2a,
randomized, double-blind, placebo-controlled, single ascending-dose study to
evaluate the safety and efficacy of naldemedine in patients with chronic
non-cancer pain and opioid-induced bowel dysfunction. J Pain. 2016
Apr;17(4S):S94. doi: 10.1016/j.jpain.2016.01.456. PubMed PMID: 28162732.

2: Migoya E, Fukumura K, Yamada T, Arjona Ferreira J. (426) Effect of
naldemedine, a peripherally acting μ-opioid receptor antagonist, on QT interval.
J Pain. 2016 Apr;17(4S):S81. doi: 10.1016/j.jpain.2016.01.403. PubMed PMID:
28162674.

3: Kim AP, Baker DE. Daclizumab. Hosp Pharm. 2016 Dec;51(11):928-939. doi:
10.1310/hpj5111-928. PubMed PMID: 28057953; PubMed Central PMCID: PMC5199226.